These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 9038376

  • 1. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation.
    Burke CL, Lemmon MA, Coren BA, Engelman DM, Stern DF.
    Oncogene; 1997 Feb 13; 14(6):687-96. PubMed ID: 9038376
    [Abstract] [Full Text] [Related]

  • 2. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo.
    Lofts FJ, Hurst HC, Sternberg MJ, Gullick WJ.
    Oncogene; 1993 Oct 13; 8(10):2813-20. PubMed ID: 8104327
    [Abstract] [Full Text] [Related]

  • 3. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.
    Zhang HT, O'Rourke DM, Zhao H, Murali R, Mikami Y, Davis JG, Greene MI, Qian X.
    Oncogene; 1998 Jun 04; 16(22):2835-42. PubMed ID: 9671404
    [Abstract] [Full Text] [Related]

  • 4. Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation.
    Qian X, Dougall WC, Fei Z, Greene MI.
    Oncogene; 1995 Jan 05; 10(1):211-9. PubMed ID: 7824275
    [Abstract] [Full Text] [Related]

  • 5. Oncogenic activation of the PDGF beta receptor by the transmembrane domain of p185neu*.
    Petti LM, Irusta PM, DiMaio D.
    Oncogene; 1998 Feb 19; 16(7):843-51. PubMed ID: 9484775
    [Abstract] [Full Text] [Related]

  • 6. Dimer interface of transmembrane domains for neu/erbB-2 receptor dimerization and transforming activation: a model revealed by molecular dynamics simulations.
    Sajot N, Genest M.
    J Biomol Struct Dyn; 2001 Aug 19; 19(1):15-31. PubMed ID: 11565846
    [Abstract] [Full Text] [Related]

  • 7. The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling.
    Kumagai T, Davis JG, Horie T, O'Rourke DM, Greene MI.
    Proc Natl Acad Sci U S A; 2001 May 08; 98(10):5526-31. PubMed ID: 11320205
    [Abstract] [Full Text] [Related]

  • 8. Specific locations of hydrophilic amino acids in constructed transmembrane ligands of the platelet-derived growth factor beta receptor.
    Freeman-Cook LL, Edwards AP, Dixon AM, Yates KE, Ely L, Engelman DM, Dimaio D.
    J Mol Biol; 2005 Jan 28; 345(4):907-21. PubMed ID: 15588835
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein.
    Qian X, O'Rourke DM, Zhao H, Greene MI.
    Oncogene; 1996 Nov 21; 13(10):2149-57. PubMed ID: 8950982
    [Abstract] [Full Text] [Related]

  • 10. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
    Weiner DB, Kokai Y, Wada T, Cohen JA, Williams WV, Greene MI.
    Oncogene; 1989 Oct 21; 4(10):1175-83. PubMed ID: 2571965
    [Abstract] [Full Text] [Related]

  • 11. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation.
    Groysman M, Nagano M, Shaanan B, Katzav S.
    Oncogene; 1998 Sep 24; 17(12):1597-606. PubMed ID: 9794237
    [Abstract] [Full Text] [Related]

  • 12. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.
    Wai DH, Knezevich SR, Lucas T, Jansen B, Kay RJ, Sorensen PH.
    Oncogene; 2000 Feb 17; 19(7):906-15. PubMed ID: 10702799
    [Abstract] [Full Text] [Related]

  • 13. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
    Pinkas-Kramarski R, Lenferink AE, Bacus SS, Lyass L, van de Poll ML, Klapper LN, Tzahar E, Sela M, van Zoelen EJ, Yarden Y.
    Oncogene; 1998 Mar 12; 16(10):1249-58. PubMed ID: 9546426
    [Abstract] [Full Text] [Related]

  • 14. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies.
    Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI.
    Oncogene; 1994 Aug 12; 9(8):2109-23. PubMed ID: 7913542
    [Abstract] [Full Text] [Related]

  • 15. A basic peptide within the juxtamembrane region is required for EGF receptor dimerization.
    Aifa S, Aydin J, Nordvall G, Lundström I, Svensson SP, Hermanson O.
    Exp Cell Res; 2005 Jan 01; 302(1):108-14. PubMed ID: 15541730
    [Abstract] [Full Text] [Related]

  • 16. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
    Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI.
    Nature; 1989 May 18; 339(6221):230-1. PubMed ID: 2654648
    [Abstract] [Full Text] [Related]

  • 17. Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity.
    Tognon CE, Mackereth CD, Somasiri AM, McIntosh LP, Sorensen PH.
    Mol Cell Biol; 2004 Jun 18; 24(11):4636-50. PubMed ID: 15143160
    [Abstract] [Full Text] [Related]

  • 18. Activation of phosphatidylinositol 3-kinase is necessary for differentiation of FDC-P1 cells following stimulation of type III receptor tyrosine kinases.
    Kubota Y, Angelotti T, Niederfellner G, Herbst R, Ullrich A.
    Cell Growth Differ; 1998 Mar 18; 9(3):247-56. PubMed ID: 9543391
    [Abstract] [Full Text] [Related]

  • 19. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
    Michieli P, Basilico C, Pennacchietti S, Maffè A, Tamagnone L, Giordano S, Bardelli A, Comoglio PM.
    Oncogene; 1999 Sep 16; 18(37):5221-31. PubMed ID: 10498872
    [Abstract] [Full Text] [Related]

  • 20. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.
    Vempati S, Reindl C, Wolf U, Kern R, Petropoulos K, Naidu VM, Buske C, Hiddemann W, Kohl TM, Spiekermann K.
    Clin Cancer Res; 2008 Jul 15; 14(14):4437-45. PubMed ID: 18628457
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.